INKINE PHARMACEUTICAL CO INC 4
4 · INKINE PHARMACEUTICAL CO INC · Filed Oct 4, 2005
Insider Transaction Report
Form 4
Cullen John
Senior V.P. & General Counsel
Transactions
- Disposition to Issuer
Copmmon Stock (right to buy)
2005-09-30−50,000→ 0 totalExercise: $3.05Exp: 2015-03-01→ Common Stock (50,000 underlying)
Footnotes (1)
- [F1]All of the options described above were converted in the merger into options to purchase Salix common stock based on an exchange ratio of 0.1737. These options, which are fully vested, now represent the right to purchase 8,685 shares of Salix common stock at a weighted average exercise price of $17.56 per share.